Opportunity ID: 309854

General Information

Document Type: Grants Notice
Funding Opportunity Number: PA-19-033
Funding Opportunity Title: Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R41/R42 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.121 — Oral Diseases and Disorders Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Oct 24, 2018
Last Updated Date: Oct 24, 2018
Original Closing Date for Applications: Sep 05, 2021
Current Closing Date for Applications: Sep 05, 2021
Archive Date: Oct 11, 2021
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

Additional Information

Agency Name: National Institutes of Health
Description: The goal of this funding opportunity announcement (FOA) is to solicit applications from small business concerns (SBCs) to initiate early research ultimately leading to the commercialization of understudied proteins identified in the “Illuminating the Druggable Genome” project (IDG; https://commonfund.nih.gov/idg/index ). The purpose of the IDG is to reveal the function of selected understudied proteins in the druggable genome. Organized as a consortium, the project consists of multiple Data and Resource Generation Centers (DRGCs), a Knowledge Management Center (KMC), a Resource Dissemination and Outreach Center (RDOC) and projects developing Cutting Edge Informatics Tools (CEITs). Small businesses are expected to complement the IDG Centers by proposing projects to commercially validate reagents, data or experimental approaches. Projects could range from early proof-of-concept demonstration and assay development/validation to the initiation of preclinical drug discovery projects.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PA-19-033.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email: FBOWebmaster@OD.NIH.GOV
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-E Use for due dates on or before May 24, 2020 PKG00245838 Dec 05, 2018 May 24, 2020 View
FORMS-F Use for due dates on or after May 25, 2020 PKG00260262 Dec 05, 2018 Sep 05, 2021 View

Package 1

Mandatory forms

309854 RR_SF424_2_0-2.0.pdf

309854 PHS398_CoverPageSupplement_4_0-4.0.pdf

309854 RR_OtherProjectInfo_1_4-1.4.pdf

309854 PerformanceSite_2_0-2.0.pdf

309854 RR_KeyPersonExpanded_2_0-2.0.pdf

309854 RR_Budget_1_4-1.4.pdf

309854 RR_SubawardBudget30_1_4-1.4.pdf

309854 PHS398_ResearchPlan_4_0-4.0.pdf

309854 SBIR_STTR_Information_1_2-1.2.pdf

Optional forms

309854 PHS_AssignmentRequestForm_2_0-2.0.pdf

Package 2

Mandatory forms

309854 RR_SF424_2_0-2.0.pdf

309854 PHS398_CoverPageSupplement_5_0-5.0.pdf

309854 RR_OtherProjectInfo_1_4-1.4.pdf

309854 PerformanceSite_2_0-2.0.pdf

309854 RR_KeyPersonExpanded_2_0-2.0.pdf

309854 RR_Budget_1_4-1.4.pdf

309854 RR_SubawardBudget30_1_4-1.4.pdf

309854 PHS398_ResearchPlan_4_0-4.0.pdf

309854 SBIR_STTR_Information_1_3-1.3.pdf

309854 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf

Optional forms

309854 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-09T08:56:52-05:00

Share This Post, Choose Your Platform!

About the Author: